news
Tiny antibody component could treat or prevent SARS-CoV-2
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
List view / Grid view
Immunology
article
Powering forward – Genomics England’s COVID-19 response
Genomics England has launched a next-generation genomic research platform that will play a key role in the response to COVID-19. It is hoped this research environment will transform how genomic data is made usable for global biopharma and academic scientists, providing world‑class patient data security, while enabling the flexibility required…
video
On-demand webinar: Leveraging advances in predesigned synthetic sgRNA for highly functional and specific CRISPR-Cas9 gene knockout
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
article
Flow cytometry in neglected tropical diseases – a focus on leishmaniasis
The World Health Organization (WHO) identifies leishmaniasis as a neglected tropical disease for which new treatments are vitally needed. Leishmaniasis primarily affects people in South America, East Africa and Asia, especially those weakened by malnutrition and poverty. To help those with this disfiguring and potentially life-threatening parasitic disease, the European…
article
Oncology meets immunology – antibody-mediated regulation of the immune response
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
news
Treatments for macrophage activation syndrome could reduce COVID-19 mortality
Researchers suggest possible therapies for macrophage activation syndrome (MAS), a feature of cytokine storm and a major cause of death in severe COVID-19 patients.
whitepaper
Application note: Human iPS cells modified with Edit-R™ CRISPR-Cas9 reagents
Modify the genome and modulate expression of genes within human iPS cells with Dharmacon™ Edit-R CRISPR reagents.
news
Bioengineered vaccine shows efficacy at protecting mice from COVID-19
Researchers have developed a novel vaccine using nucleotide untranslated regions that successfully protected mice from COVID-19.
news
NIAID unveils new Centers for Research in Emerging Infectious Diseases (CREID)
The global network of centers will investigate where pathogens emerge and how they adapt to cause disease in humans, in the hopes of increasing our preparedness for future disease outbreaks.
news
UK government to invest £8.4 million into COVID-19 immunology research
The UK government will invest £8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.
news
Novel protection pathway makes cells resistant to Ebola and coronavirus infection, report scientists
Researchers reveal that activating the MHC class II transactivator (CIITA) and CD74 genes protected cells against infection by Ebola and SARS-CoV-2.
news
Researchers halt type 1 diabetes onset by denervating the pancreas
Scientists denervated the pancreas using surgery or pharmacological agents to protect it from immune-mediated beta cell destruction, preventing the onset of type 1 diabetes.
news
Tracking SARS-CoV-2 evolution: notable mutations and potential targets
Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
news
Researchers suggest IgA antibodies are better at neutralising SARS-CoV-2
Scientists have developed a novel secretory immunoglobulin A (sIgA) serotype antibody that binds more effectively to the spike protein of SARS-CoV-2 than some IgG antibodies.
